First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors
MSLN-TTC showed good tolerability, but the maximum tolerated dose could not be determined due to discontinuations after antidrug antibody formation. Stable disease was observed in 12 out of 36 patients.
Authors
- Agostino Tafuri (ORCID: https://orcid.org/0000-0001-7911-9263)
- Friedhelm Bladt
- Danilo Otávio Laurenti Ferreira (ORCID: https://orcid.org/0000-0002-2227-0621)
- K. Jalkanen (ORCID: https://orcid.org/0000-0003-4497-5371)
- Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
- Raffit Hassan (ORCID: https://orcid.org/0000-0002-4012-3633)
- Vivek Subbiah (ORCID: https://orcid.org/0000-0002-6064-6837)
- Vicki Jardine
- Adriaan Cleton (ORCID: https://orcid.org/0000-0002-7413-8585)
- Frank I. Lin (ORCID: https://orcid.org/0000-0003-3539-1454)
- Anna Rachel Minchom (ORCID: https://orcid.org/0000-0002-9339-7101)
- Daan G. Knapen (ORCID: https://orcid.org/0000-0002-2523-137X)
- Hartwig Hennekes (ORCID: https://orcid.org/0009-0006-8546-5537)
- O. Lindén
- J. Pinkert
Institutions
- University Medical Center Groningen (NL)
- The University of Texas MD Anderson Cancer Center (US)
- Institute of Cancer Research (GB)
- Bayer (United States) (US)
- Lund University (SE)
- Helsinki University Hospital (FI)
- The Netherlands Cancer Institute (NL)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105905
- Citations
- 2
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.04